PDT remains an effective intervention for specific subtypes of nAMD refractory to anti-VEGF therapy and several retinal and choroidal diseases (e.g., CSC, hemangioma, and other tumors) despite the recent advancements in anti-VEGF therapy for nAMD, including PCV and PNV. The gene discussed is VEGFA; the disease is hemangioma.